Spyre Therapeutics, Inc. Common Stock (SYRE)
Health Care – PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 112
- Market Cap
- $9.3B
About Spyre Therapeutics, Inc. Common Stock
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
SentiSense also tracks daily options readings for Spyre Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Spyre Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.